[HTML][HTML] A smart and versatile theranostic nanomedicine platform based on nanoporphyrin

…, JH Walton, SR Cherry, DJ Rowland, D Kukis… - Nature …, 2014 - nature.com
Multifunctional nanoparticles with combined diagnostic and therapeutic functions show
great promise towards personalized nanomedicine. However, attaining consistently high …

Synthesis of 64Cu-Labeled Magnetic Nanoparticles for Multimodal Imaging

BR Jarrett, B Gustafsson, DL Kukis… - Bioconjugate …, 2008 - ACS Publications
Complementary imaging modalities provide more information than either method alone can
yield and we have developed a dual-mode imaging probe for combined magnetic …

A Novel Method to Label Preformed Liposomes with 64Cu for Positron Emission Tomography (PET) Imaging

JW Seo, H Zhang, DL Kukis, CF Meares… - Bioconjugate …, 2008 - ACS Publications
Radiolabeling of liposomes with 64 Cu (t 1/2 = 12.7 h) is attractive for molecular imaging
and monitoring drug delivery. A simple chelation procedure, performed at a low temperature …

[PDF][PDF] Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent

SV Deshpande, SJ DeNardo, DL Kukis… - Journal of nuclear …, 1990 - Soc Nuclear Med
Yttrium-90-Labeled Monoclonal Antibody for Therapy: Labeling by a New Macrocycic
Bifunctional Chelating Agent Page 1 cated that this may be due to the loss of @ÂYfrom the …

[HTML][HTML] Persistent neuroinflammation and cognitive impairment in a rat model of acute diisopropylfluorophosphate intoxication

…, DJ Rowland, CN Banks, AT Austin, DL Kukis… - Journal of …, 2016 - Springer
Background Acute intoxication with organophosphorus (OP) cholinesterase inhibitors can
trigger convulsions that progress to life-threatening status epilepticus. Survivors face long-term …

[PDF][PDF] Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates

DL Kukis, SJ DeNardo, GL DeNardo… - Journal of Nuclear …, 1998 - Soc Nuclear Med
Radioimmunotherapy (RIT) with^-labeled immunoconjugates has shown promise in clinical
trials. The macrocyclic chelating agent 1, 4, 7, 10-tetraazacyclododecane-N, N', N", N"'-…

Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates

DL Kukis, GL DeNardo, SJ DeNardo, GR Mirick… - Cancer research, 1995 - AACR
Trial therapy for lyphoma with the radiolabeled chelate-antibody conjugate 67 Cu-2IT-BAT-Lym-1
has been promising. It is desirable to deliver therapeutic doses of radiometal using a …

Enhanced Therapeutic Index of Radioimmunotherapy (RIT) in Prostate Cancer Patients: Comparison of Radiation Dosimetry for 1,4,7,10-Tetraazacyclododecane-N,N′,N″,N …

…, CM Richman, RT O'Donnell, PN Lara, DL Kukis… - Clinical cancer …, 2003 - AACR
Purpose: Radioimmunotherapy delivered by radiometal immunoconjugates and followed by
marrow support is dose limited by deposition of radioactivity in normal organs. To increase …

[HTML][HTML] Alginate hydrogels allow for bioactive and sustained release of VEGF-C and VEGF-D for lymphangiogenic therapeutic applications

KT Campbell, DJ Hadley, DL Kukis, EA Silva - PloS one, 2017 - journals.plos.org
Lymphatic dysfunction is associated with the progression of many cardiovascular disorders
due to their role in maintaining tissue fluid homeostasis. Promoting new lymphatic vessels (…

[PDF][PDF] A Clinical trial of radioimmunotherapy with 67Cu-21T-BAT-Lym-1 for non-Hodgkin's lymphoma

RT O'Donnell, GL DeNardo, DL Kukis… - Journal of Nuclear …, 1999 - Soc Nuclear Med
Resufts: 67Cu-2lT-BAT-Lym-1providedgoodimagingof NHL and favorable radiation dosimetry.
The mean radiation ratios of tumor to body and tumor to marrow were 28: 1 and 15: 1, …